Get started
Author

David J. Serisier

Observed names: D J Serisier, D Serisier, D. J. Serisier, D. Serisier, D.J. Serisier, DAVID J. SERISIER, David J Serisier, David J. SERISIER, David SERISIER, David Serisier, Serisier, D., Serisier, David John
Observed institutions: Translational Research Institute, Mater Health Services, The University of Queensland, Southampton General Hospital, University Hospital Southampton NHS Foundation Trust, Mater Research, Mater Adult Hospital
ORCID: 0000-0002-7484-7904
Observed ORCID: 0000-0002-7484-7904
OpenAlex ID: A5057403755
Effect of Long-term, Low-Dose Erythromycin on Pulmonary Exacerbations Among Patients With Non–Cystic Fibrosis Bronchiectasis
2013 · David J. Serisier, Megan L. Martin, et al. · JAMA · 419
Characterization of Bacterial Community Diversity in Cystic Fibrosis Lung Infections by Use of 16S Ribosomal DNA Terminal Restriction Fragment Length Polymorphism Profiling
2004 · G. B. Rogers, M. P. Carroll, et al. · Journal of Clinical Microbiology · 319
Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial
2013 · David J Serisier, Diana Bilton, et al. · Thorax · 249
PDF
A Novel Microbiota Stratification System Predicts Future Exacerbations in Bronchiectasis
2014 · Geraint B. Rogers, Nur Masirah M. Zain, et al. · Annals of the American Thoracic Society · 244
The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial
2014 · Geraint B Rogers, Kenneth D Bruce, et al. · The Lancet Respiratory Medicine · 217
Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition
2013 · Geraint B Rogers, Christopher J van der Gast, et al. · Thorax · 207
PDF
Use of 16S rRNA Gene Profiling by Terminal Restriction Fragment Length Polymorphism Analysis To Compare Bacterial Communities in Sputum and Mouthwash Samples from Patients with Cystic Fibrosis
2006 · G. B. Rogers, M. P. Carroll, et al. · Journal of Clinical Microbiology · 151
Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases
2013 · David J Serisier · The Lancet Respiratory Medicine · 145
Matrix Metalloproteinases Vary with Airway Microbiota Composition and Lung Function in Non–Cystic Fibrosis Bronchiectasis
2015 · Steven L. Taylor, Geraint B. Rogers, et al. · Annals of the American Thoracic Society · 99
Respiratory microbiota: addressing clinical questions, informing clinical practice
2014 · Geraint B Rogers, Dominick Shaw, et al. · Thorax · 96
PDF
Bacterial activity in cystic fibrosis lung infections
2005 · Geraint B Rogers, Mary P Carroll, et al. · Respiratory Research · 94
PDF
Predominant pathogen competition and core microbiota divergence in chronic airway infection
2014 · Geraint B Rogers, Christopher J van der Gast, et al. · The ISME Journal · 73
PDF
Macrorheology of cystic fibrosis, chronic obstructive pulmonary disease & normal sputum
2009 · David J Serisier, Mary P Carroll, et al. · Respiratory Research · 64
PDF
Determining Cystic Fibrosis-Affected Lung Microbiology: Comparison of Spontaneous and Serially Induced Sputum Samples by Use of Terminal Restriction Fragment Length Polymorphism Profiling
2009 · Geraint B. Rogers, Stuart Skelton, et al. · Journal of Clinical Microbiology · 59
Dailyversusweekly azithromycin in cystic fibrosis patients
2007 · J. McCormack, S. Bell, et al. · European Respiratory Journal · 56
PDF
Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations
2011 · D.J. Serisier, M.L. Martin · Respiratory Medicine · 55
PDF
Inhaled heparin in cystic fibrosis
2006 · D. J. Serisier, J. K. Shute, et al. · European Respiratory Journal · 41
PDF
Bayesian Estimation of Tobramycin Exposure in Patients with Cystic Fibrosis
2016 · Michael A. Barras, David Serisier, et al. · Antimicrobial Agents and Chemotherapy · 39
Eradication of pulmonary methicillin-resistant staphylococcus aureus (MRSA) in cystic fibrosis with linezolid
2004 · David J Serisier, Graeme Jones, et al. · Journal of Cystic Fibrosis · 31
Alveolar haemorrhage in anti-glomerular basement membrane disease without detectable antibodies by conventional assays
2006 · D J Serisier · Thorax · 29
PDF
Australasian respiratory and emergency physicians do not use the pneumonia severity index in community‐acquired pneumonia
2012 · DAVID J. SERISIER, SOPHIE WILLIAMS, et al. · Respirology · 27
Adult Non-Cystic Fibrosis Bronchiectasis Is Characterised by Airway Luminal Th17 Pathway Activation
2015 · Alice C.-H. Chen, Megan L. Martin, et al. · PLoS ONE · 24
PDF
Inhaled antibiotics for lower respiratory tract infections: Focus on ciprofloxacin
2012 · Serisier, D. · Drugs of today · 23
Effect of Albuterol on Maximal Exercise Capacity in Cystic Fibrosis
2007 · David J. Serisier, Andrew D. Coates, et al. · CHEST Journal · 19
Nocardia paucivorans – A cause of disseminated Nocardiosis
2006 · Timothy James Gray, David J. Serisier, et al. · Journal of Infection · 16
Works count: 75
Citation count: 2,955
H-index: 23
I10-index: 32
Year
Topic
Type